Core Insights - Daxor Corporation announced new data indicating that blood volume analysis (BVA) can significantly improve survival rates for hospitalized heart failure patients when performed prior to discharge [1][2] Company Overview - Daxor Corporation (Nasdaq: DXR) is a leader in blood volume measurement technology, focusing on innovation in blood volume testing [3] - The company developed the BVA-100, the only FDA-cleared diagnostic blood test for quantifying blood volume status and composition [3] - Over 65,000 tests have been conducted in leading U.S. hospitals, contributing to improved performance metrics and reduced mortality and readmissions in heart failure and critical care [3] Study Findings - A study involving 1,237 hospitalized heart failure patients showed that those identified as "euvolemic" through BVA had significantly better one-year survival rates compared to those who were hypervolemic [2][5] - The hazard ratio for death was found to be 2.61 times higher in the hypervolemic group compared to the euvolemic group, with a statistically significant p-value of 0.002 [5] - The correlation between blood volume status and survival outcomes remained significant even after adjusting for comorbidities, underscoring the clinical value of BVA [5] Implications for Heart Failure Management - The findings suggest that BVA can be a critical tool for optimizing treatment and ensuring proper decongestion before patient discharge [2] - The study supports the notion that precision volume management guided by BVA technology can save lives and improve outcomes for heart failure patients [2]